Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The
acute efficacy of ketamine in TRD has been demonstrated in replicated randomised …

Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported. We
aimed to evaluate acute anti-SI effects of single-dose ketamine in different …

Background Bipolar depression accounts for most of the disease duration in type I and type
II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals …

Objective Suicide is a major cause of death in adolescents with limited treatment options.
Ketamine and its enantiomers have shown rapid anti-suicidal effects in adults with major …

The emerging roles of ketamine and esketamine as effective rapid-acting antidepressants
hold promise for patients suffering from treatment-resistant depression and/or major …

Introduction Ketamine intravenous therapy (KIT) appears effective for treating depression in
controlled trials testing a short series of infusions. A rapidly proliferating number of clinics …

Background In recent years, ketamine and esketamine treatment have demonstrated rapid
antidepressant effects in adults with treatment-resistant depression (TRD). Hitherto …

Background: Clinical trials have demonstrated rapid antidepressant effects with intravenous
(IV) ketamine for major depressive disorder, with relatively less research specifically for …